Rep. Gilbert Ray Cisneros, Jr. Acquires Biogen Inc. (NASDAQ:BIIB) Stock

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on July 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Biogen stock on June 5th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of The Descartes Systems Group (NASDAQ:DSGX) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Texas Roadhouse (NASDAQ:TXRH) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Texas Capital Bancshares (NASDAQ:TCBI) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Microchip Technology (NASDAQ:MCHP) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 6/30/2026.

Biogen Price Performance

Shares of NASDAQ BIIB remained flat at $216.12 during mid-day trading on Friday. 1,154,423 shares of the stock traded hands, compared to its average volume of 1,149,002. The company has a market capitalization of $31.91 billion, a P/E ratio of 23.19 and a beta of 0.16. Biogen Inc. has a 52-week low of $121.05 and a 52-week high of $219.72. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The business has a 50-day moving average of $196.61 and a 200-day moving average of $187.03.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period last year, the company earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities analysts anticipate that Biogen Inc. will post 13.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BIIB. Wall Street Zen upgraded shares of Biogen from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Wedbush increased their price objective on shares of Biogen from $191.00 to $196.00 and gave the stock a “neutral” rating in a research report on Thursday, April 30th. Citigroup raised their price objective on shares of Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Needham & Company LLC upped their target price on Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Oppenheimer increased their price target on Biogen from $275.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Biogen has an average rating of “Moderate Buy” and an average price target of $217.41.

Hedge Funds Weigh In On Biogen

A number of hedge funds have recently added to or reduced their stakes in BIIB. Versant Capital Management Inc raised its position in shares of Biogen by 15.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,539 shares of the biotechnology company’s stock worth $333,000 after acquiring an additional 208 shares in the last quarter. Sapient Capital LLC purchased a new position in shares of Biogen in the 1st quarter worth approximately $210,000. Parallel Advisors LLC raised its stake in shares of Biogen by 1.5% during the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after acquiring an additional 65 shares in the last quarter. Caerus Investment Advisors LLC lifted its position in Biogen by 5.0% during the first quarter. Caerus Investment Advisors LLC now owns 2,801 shares of the biotechnology company’s stock valued at $514,000 after acquiring an additional 134 shares during the last quarter. Finally, Financial Solutions Advisory Group Inc. purchased a new position in Biogen in the first quarter worth $252,000. 87.93% of the stock is currently owned by institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.